🇺🇸 Onasemnogene Abeparvovec-xioi in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 3 reports (23.08%)
  2. Fatigue — 2 reports (15.38%)
  3. Aspiration — 1 report (7.69%)
  4. Asthenia — 1 report (7.69%)
  5. Decreased Appetite — 1 report (7.69%)
  6. Dysphagia — 1 report (7.69%)
  7. Inflammatory Marker Increased — 1 report (7.69%)
  8. Liver Injury — 1 report (7.69%)
  9. Muscular Weakness — 1 report (7.69%)
  10. Necrotising Enterocolitis Neonatal — 1 report (7.69%)

Source database →

Other Neurology approved in United States

Frequently asked questions

Is Onasemnogene Abeparvovec-xioi approved in United States?

Onasemnogene Abeparvovec-xioi does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Onasemnogene Abeparvovec-xioi in United States?

Novartis Gene Therapies is the originator. The local marketing authorisation holder may differ — check the official source linked above.